Literature DB >> 17332330

Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.

Mauro Provinciali1, Francesca Papalini, Fiorenza Orlando, Sara Pierpaoli, Alessia Donnini, Paolo Morazzoni, Antonella Riva, Arianna Smorlesi.   

Abstract

Silybin, a main component of the milk thistle of Silybum marianum, has been reported to possess anticancer activity. We investigated the effects of IdB 1016, a complex of silybin with phosphatidylcholine, on the development of mammary tumors appearing spontaneously in HER-2/neu transgenic mice. The mechanisms involved in the antitumor effect of IdB 1016 were evaluated by studying the apoptosis, senescent-like growth arrest, intratumoral leukocyte infiltrate, and the expression of HER-2/neu and p53 in tumoral mammary glands from transgenic mice and in human breast SKBR3 tumor cells. The administration of IdB 1016 delayed the development of spontaneous mammary tumors, reduced the number and size of mammary tumor masses, and diminished lung metastasization in HER-2/neu transgenic mice. In tumoral mammary glands from IdB 1016-treated mice, a down-regulation of HER-2/neu gene expression was associated with an increased senescent-like growth arrest of tumor cells, and an increased infiltrate of neutrophils, CD4, and CD8 T cells. Both senescent-like growth arrest and apoptosis were significantly increased and were associated with a reduced p185(HER-2/neu) protein and an increased p53 mRNA in SKBR3 in vitro treated with IdB 1016 in comparison with control cells. The results show the antitumor effect of IdB 1016 in the development of spontaneous mammary tumors in HER-2/neu transgenic mice. The effect of IdB 1016 might be related to the down-regulation of HER-2/neu expression and the induction of senescent-like growth arrest and apoptosis through a p53-mediated pathway in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332330     DOI: 10.1158/0008-5472.CAN-06-2601

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.

Authors:  Brandon T Gufford; Gang Chen; Ana G Vergara; Philip Lazarus; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-06-12       Impact factor: 3.922

Review 2.  Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

Review 3.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

Review 4.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

5.  Foxp3 expression in p53-dependent DNA damage responses.

Authors:  Da-Jung Jung; Dong-Hoon Jin; Seung-Woo Hong; Jee-Eun Kim; Jae-Sik Shin; Daejin Kim; Byung-Joo Cho; Young-Il Hwang; Jae-Seung Kang; Wang-Jae Lee
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 6.  Multitargeted therapy of cancer by silymarin.

Authors:  Kumaraguruparan Ramasamy; Rajesh Agarwal
Journal:  Cancer Lett       Date:  2008-05-09       Impact factor: 8.679

7.  Comparing the Effect of Silybin and Silybin Advanced™ on Viability and HER2 Expression on the Human Breast Cancer SKBR3 Cell Line by no Serum Starvation.

Authors:  Narges Mahmoodi; Nasrin Motamed; Seyed Hassan Paylakhi; Nosrat O Mahmoodi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

8.  New Aspects of Silibinin Stereoisomers and their 3-O-galloyl Derivatives on Cytotoxicity and Ceramide Metabolism in Hep G2 hepatocarcinoma Cell Line.

Authors:  Mahdi Mashhadi Akbar Boojar; Mahsa Hassanipour; Shahram Ejtemaei Mehr; Masoud Mashhadi Akbar Boojar; Ahmad Reza Dehpour
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

9.  Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation.

Authors:  Kwan Yeol Yang; Du Hyeong Hwang; Abid Mehmood Yousaf; Dong Wuk Kim; Young-Jun Shin; Ok-Nam Bae; Yong-Il Kim; Jong Oh Kim; Chul Soon Yong; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2013-08-28

Review 10.  Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy.

Authors:  Marco Malavolta; Massimo Bracci; Lory Santarelli; Md Abu Sayeed; Elisa Pierpaoli; Robertina Giacconi; Laura Costarelli; Francesco Piacenza; Andrea Basso; Maurizio Cardelli; Mauro Provinciali
Journal:  Mediators Inflamm       Date:  2018-02-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.